Importance of screening for comorbidities in psoriasis patients

Expert Review of Dermatology

Volumn 3, Issue 2, 2008, Pages 133-135

  Gulliver, Wayne P ^a,b,c  

^a NewLab Clinical Research Inc

^b Newfound Genomics ^*

^c MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HLA C ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 23; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA;

CARDIOVASCULAR DISEASE; COMORBIDITY; CROHN DISEASE; DEPRESSION; DIABETES MELLITUS; DRUG EFFICACY; DRUG TARGETING; EDITORIAL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MORTALITY; OBESITY; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; SMOKING;

EID: 53649099717     PISSN: 17469872     EISSN: None     Source Type: Journal    
DOI: 10.1586/17469872.3.2.133     Document Type: Editorial

References (17)

1. Karlamangla A. Comorbidity: From Bedside to Bench. Summary of NIA/ JAGS, R13 Conference, May (2005).
2. Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch. Intern. Med. 162, 2269-2279 (2002).
3. Kriegsman DM, van Eijk JT, Penninx BW, Deeg DJ, Boeke AJ. Does family support buffer the impact of specific chronic diseases on mobility in community-dwelling elderly? Disabil. Rehabil. 19, 71-83 (1997).
4. (CBO 9-18-2002); CBO Testimony: Dan L Crippen, Director (1997).
5. Gulliver WP. Genetic targets for the future treatment of psoriasis including HLA-Cw6. Presented at: 21st World Congress of Dermatology, Buenos Aires, Argentina, 30 September-5 October 2007.
6. Rahman P, O'Reilly DD. Psoriatic arthritis: genetic susceptibility and pharmacogenetics. Pharmacogenomics 9(2), 195-205(11) (2008).
7. Dueer RH, Taylor KD, Brant SR et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314, 1461-1463 (2006).
8. Cargill M, Schrodi SJ, Chang M et al. A large-scale genetic association study confirms IL-12B and leads to the identification of IL-23R as psoriasis-risk genes. Am. J. Hum. Genet. 80, 273-290 (2007).
9. Victor FC, Gottlieb AB, Menter A. Changing paradigms in dermatology: tumor necrosis factor α (TNF-α) blockade in psoriasis and psoriatic arthritis. Clin. Dermatol. 21, 392-397 (2003).
10. Krueger G G, Langley RG, Leonardi C et al. A human interleukin-12/ 23 monoclonal antibody for the treatment of psoriasis. N. Engl J. Med. 356, 580-592 (2007).
11. Mandelboim O, Reyburn HT, Valés-Gómez M et al. Protection from lysis by natural killer cells of group 1 and 2 specificity is mediated by residue 80 in human histocompatibility leukocyte antigen c alleles and also occurs with empty major histocompatibility of complex molecules. J. Exp. Med. 184, 913-922 (1996).
12. Gelfand JM, Troxel AB, Lewis JD et al. The risk of mortality in patients with psoriasis. Arch. Dermatol. 143(12), 1493-1499 (2007).
13. Gulliver WP. Comorbidities associated with the Newfoundland and Labrador founder population. Presented at: 21st World Congress of Dermatology, Buenos Aires, Argentina, 30 September-5 October, 2007.
14. Rosenberg P, Urwitz H, Johannesson A et al. Psoriasis patients with diabetes Type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J. Hepatol. 46(6), 1111-1118 (2007).
15. Prodanovich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J. Am. Acad. Dermatol. 52, 262-267 (2005).
16. Greenberg J, Lin SL, Decktor D et al. Association of duration of TNF antagonist treatment with reduction in cardiovascular outcomes in RA patients. Arthritis Rheum. 54(9), S927 (2006) (Abstract).
17. Gulliver WP. Comorbidities associated with Newfoundland and Labrador founder population. Presented at: European Academy of Dermatology and Venereology, Vienna, Austria, 16-20 May, 2007.